ER&D services largest pure-play, Alten, has ambitions as a clinical trials contract research organization (CRO). During Q2 2021, the company completed the acquisition of Cmed. Cmed, a clinical trial CRO based in the UK. It is a small firm with EUR 20m in revenues and 180 consultants. It has specialized in oncology, immuno-oncology, cell therapy, and rare disease.
Thermo Fisher Makes A Massive Acquisition with PPD
Become a ERD Services premium reader to access all of your content, by contacting us at dominique@ERDservices.org.
NNIT Shows A Path to Growth in Pharma
We rarely talked about Denmark-based NNIT. The company is the former IT captive of Danish pharmaceutical firm Novo Nordisk, thus the name NNIT, which stands for Novo Nordisk IT.
Dassault Sytems Lowers its Q1 2020 Guidance: Read-Throughs for the ER&D Service Industry
Dassault Systems lowered it Q1 2020: the company is now expecting revenue growth in the range of 14%-17%, down from a 20-23% guidance (that includes the acquisition of Medidata). The company has suffered from weaker than expected new license and services revenues. Meanwhile, revenues of Medidata were on a “momentum and license renewals were up too.
Veeva Demonstrates the Clinical Trials Market is Fast-Growing. An opportunity for ER&D Vendors
eeva is a Wall Street darling with an eye-popping market cap of $21bn. The uniqueness of Veeva is that its SaaS applications run on top of Salesforce’s Clouds. This approach positions Veeva in the high-growth ecosystem of Salesforce (which grows by 20-25% each year).